Fosgonimeton

A prodrug of the small molecule ATH-1017

Fosgonimeton
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Fosgonimeton is a prodrug of the small molecule ATH-1017, which is under investigation for its potential therapeutic effects in neurodegenerative disorders, particularly Alzheimer's disease.

Mechanism of Action

Fosgonimeton is designed to enhance the activity of the hepatocyte growth factor (HGF)/c-Met signaling pathway. This pathway is involved in various cellular processes, including neurogenesis, synaptic plasticity, and neuronal survival. By activating this pathway, Fosgonimeton may help to protect neurons from degeneration and promote cognitive function.

Pharmacokinetics

As a prodrug, Fosgonimeton is converted into its active form, ATH-1017, in the body. This conversion allows for improved bioavailability and targeted delivery of the active compound to the central nervous system. The pharmacokinetic profile of Fosgonimeton is characterized by its ability to cross the blood-brain barrier, which is crucial for its intended therapeutic effects.

Clinical Development

Fosgonimeton is currently undergoing clinical trials to evaluate its safety and efficacy in patients with Alzheimer's disease. Early studies have shown promise in improving cognitive function and slowing disease progression. The drug is being developed by Athira Pharma, a biotechnology company focused on innovative treatments for neurodegenerative diseases.

Potential Benefits

The activation of the HGF/c-Met pathway by Fosgonimeton may offer several benefits for patients with neurodegenerative disorders:

• Neuroprotection: By promoting neuronal survival, Fosgonimeton may help to preserve brain function in patients with Alzheimer's disease.
• Cognitive Enhancement: The drug's effects on synaptic plasticity could lead to improvements in memory and learning.
• Disease Modification: Unlike symptomatic treatments, Fosgonimeton has the potential to modify the underlying disease process, offering a more comprehensive approach to treatment.

Challenges and Considerations

While Fosgonimeton shows promise, there are challenges to its development and use:

• Safety and Tolerability: As with any new drug, ensuring the safety and tolerability of Fosgonimeton in patients is paramount.
• Long-term Efficacy: The long-term benefits and potential side effects of Fosgonimeton need to be thoroughly evaluated in clinical trials.
• Regulatory Approval: Achieving regulatory approval requires demonstrating significant clinical benefits over existing treatments.

Related Pages

• Alzheimer's disease
• Neurodegenerative disease
• Prodrug
• Hepatocyte growth factor
• MET receptor